chore: daily update 2026-08-26

commitments.md

@@ -2,7 +2,8 @@
 type: "Reference"
 title: "Commitments"
 description: "Active work tasks, follow-ups, approvals, and scheduled items extracted from sources (web-search, git-repo, literature flywheel-sync, etc.). Personal errands live in /personal-logistics.md instead."
-tags: [commitments, work, follow-ups, distributors-2026-08-07-refresh, dong-huiqun-ji-nan-chengquan-link, liang-2026-celvivo-clinostar-positioning, guo-2026-organoid-irb-checklist-rollout]
+tags: [commitments, work, follow-ups, distributors-2026-08-07-refresh, dong-huiqun-ji-nan-chengquan-link, liang-2026-celvivo-clinostar-positioning, guo-2026-organoid-irb-checklist-rollout, celvivo-app-note-2026-clinostar-vs-orbital-shaker-positioning, aiello-2025-rc-cfd-clinostar-positioning, kim-2025-egain-3d-mea-vs-3brain-positioning, ajongbolo-2025-brain-organoid-review-cluster, tian-2025-epicardium-mtor-cardiac-expansion, tevonian-2026-vascularized-liver-mps-positioning, yang-2026-cardiac-organoid-review-positioning, shen-2026-vascularized-organoid-chinese-review, zhai-2026-skin-organoid-pemphigus-positioning, 2026-08-25]
+timestamp: 2026-08-25T18:13:00Z
 ---
 
 # Commitments
@@ -158,6 +159,34 @@ Concrete work tasks, follow-ups, approvals, and scheduled items extracted from G
 - Status: open
 - Notes: **First cardiac-epicardium paper in Robin's deep-read set** — Tian paper establishes **Torin1 (dual mTORC1/2 inhibitor, 200 nM) drives hiPSC epicardium maturation** with mature markers (TJP1/WT1/TBX18/ALDH1A2/CDH18) up + EMT markers down + proliferation markers down + fatty-acid metabolism maturation; 379 DEGs; adult-like profile vs GSE84085; YBX3 + MAFF identified as Torin1-specific TFs; **paracrine TNNI3 upregulation in hiPSC ventricular cardiomyocyte EBs co-cultured for 10 days** (epicardium-to-cardiomyocyte maturation cross-talk). **Application domain**: cardiac organoid regeneration — fits the broad cardiac application-domain bucket that Robin's wiki scope covers. **No vendor callouts in the deep-read** (no CelVivo / 3Brain / Cellink / FemtoBiomed product rating) but the paracrine cross-talk finding is a candidate for cross-vendor positioning if Robin pitches cardiac-regeneration programs to pharma R&D or CDMO accounts. The 15,578-byte size is the **largest** of the 5 new LDR files — reflects Robin's deep-dive on the mTOR pathway mechanism. Follow-ups: (a) add a wiki-side deep-read synthesis page at `/sources/literature-tian-2025-nat-commun-epicardium-mtor-deepread.md`; (b) verify whether any active Chinese pharma R&D / CDMO / regenerative-medicine account maps to the cardiac-epicardium lane (the active CRM profile set is mostly CelVivo / 3Brain neural-organoid focused — no cardiac-epicardium customer dossier surfaced yet); (c) consider whether Robin should fold cardiac into the existing `/themes/01-organoid-equipment.md` theme or open a new `theme-cardiac-regeneration.md` if cardiac papers recur.
 
+### tevonian-2026-vascularized-liver-mps-positioning: Tevonian 2026 Nat Commun vascularized liver MPS vendor-mapping + 中国药企 hepatic-IR 药筛 positioning
+- Owner: me
+- Source: git-repo-1 2026-08-25 — vault commit `089177a7` (Tevonian et al. 2026 Nat Commun vascularized liver microphysiological system, PMID 41634021, DOI 10.1038/s41467-025-68031-6; vault path `obsidian-vault/04-Literature/Deep-Reads/Vascularized-Organoids/Tevonian_2026_Nat_Commun_Vascularized_Liver_MPS.md`, **first file in new `Vascularized-Organoids/` subfolder**)
+- Due: unscheduled
+- Status: open
+- Notes: **First vascularized liver MPS paper** in Robin's deep-read set; **5-vendor product mapping retrofit applied** via the `9aa2af4c` post-publish retrofit commit (CelVivo ClinoStar / ClinoReactor + Cellink BIO X + Mimetas OrganoPlate + 3Brain HD-MEA + FemtoBiomed CellShot). Mimetas OrganoPlate is the canonical microphysiological system for the multi-channel vascularized liver architecture (PDMS + fibrin + primary hepatocytes + HUVEC) + CelVivo ClinoReactor for upstream hepatocyte maturation (Hep-Orgs source) + Cellink BIO X for the decellularized liver scaffold matrix. **Application domain**: vascularized liver MASLD/NASH 体外建模 + 个性化药筛 + 血管化类器官平台. Companion to the existing **Liang 2026** liver organoid entry (ClinoStar ⭐⭐⭐⭐ for P1-P10 long-term maturation + ClinoReactor ⭐⭐⭐⭐ for 3-track HEP/CHO/HSC perfusion) — Tevonian 血管化 dimension extends the existing Liver/ subfolder's fibrotic disease modeling story. Follow-ups: (a) add a wiki-side deep-read synthesis page at `/sources/literature-tevonian-2026-nat-commun-vascularized-liver-mps-deepread.md`; (b) cross-link Tevonian with Shen 2026 in the new Vascularized-Organoids/ subfolder to anchor a vascularized-organoid review-paper cluster; (c) verify whether the active MASLD/NASH hepatic-IR account dossier (if any in the CRM) maps to Mimetas OrganoPlate CelVivo ClinoReactor + Cellink BIO X as a triple-vendor solution.
+
+### yang-2026-cardiac-organoid-review-positioning: Yang 2026 Stem Cell Res Ther cardiac organoid review vendor-mapping + 心脏药物毒性测试 positioning
+- Owner: me
+- Source: git-repo-1 2026-08-25 — vault commit `583859a8` (Yang L et al. 2026 Stem Cell Res Ther cardiac organoid review, PMID 41963991, DOI 10.1186/s13287-026-04996-5; vault path `obsidian-vault/04-Literature/Deep-Reads/Cardiac-Organoids/Yang_2026_Stem_Cell_Res_Ther_Cardiac_Organoid_Review.md`, **first file in new `Cardiac-Organoids/` subfolder**)
+- Due: unscheduled
+- Status: open
+- Notes: **First comprehensive cardiac organoid review** in Robin's deep-read set; **5-vendor product mapping retrofit applied** via the `9aa2af4c` post-publish retrofit commit (same 5-vendor mapping as Tevonian). Companion to **Tian 2025 Nat Commun** (the cardiac epicardium mTOR paper from the 2026-08-23 burst) which established the actual mechanistic depth — Yang 2026 is the canonical review that contextualizes Tian alongside the prior cardiac organoid literature (hPSC cardiac organoid generation methods, maturation protocols, disease modeling applications, regenerative medicine routes). Covers FGF/PI3K/Wnt/BMP/Activin/RA 五大信号通路 + 三种 3D 培养策略. **Application domain**: cardiac organoid — Robin expands from the prior 2-paper Cardiac/ subfolder to a dedicated Cardiac-Organoids/ subfolder; first time Robin has opened a new subfolder explicitly for an application-domain cluster. **Robin 业务对接**: 心脏药物毒性测试 + hiPSC 衍生心脏类器官服务 + 心血管疾病建模. Follow-ups: (a) add a wiki-side deep-read synthesis page at `/sources/literature-yang-2026-stem-cell-res-ther-cardiac-organoid-review-deepread.md`; (b) pair Tian + Yang as a paired mechanistic + review cluster on `/themes/05-robin-research.md`; (c) verify whether any active Chinese pharma R&D cardiac-toxicology account maps to CelVivo + 3Brain as a paired vendor solution for hiPSC-derived cardiac organoid electrophysiology.
+
+### shen-2026-vascularized-organoid-chinese-review: Shen 2026 Chin Med J vascularized organoid systematic review for Chinese-hospital IRB positioning
+- Owner: me
+- Source: git-repo-1 2026-08-25 — vault commit `5907cdfc` (Shen Y et al. Chin Med J 2026 vascularized organoids systematic review, PMID 42268296, DOI 10.1097/CM9.0000000000004136; vault path `obsidian-vault/04-Literature/Deep-Reads/Vascularized-Organoids/Shen_2026_Chin_Med_J_Vascularized_Organoids_Review.md`, Chinese-language peer-reviewed systematic review from 华西医院, second file in new Vascularized-Organoids/ subfolder)
+- Due: unscheduled
+- Status: open
+- Notes: **Chinese-language peer-reviewed vascularized organoid systematic review** — establishes credential Chinese-hospital-academic source for Robin's active Chinese pharma R&D / CDMO customer base. Structures vascularized organoid 4 大策略 (共培养 + 转录因子诱导 + 微流控 + 生物材料支架) + 12 维对比 + 三大未来方向. **Vendor anchor mapping**: TBD — not retrofitted by `9aa2af4c` (only Tevonian + Yang got the 5-vendor retrofit). **Application domain**: vascularized organoid — adds a 2-paper cluster to the new Vascularized-Organoids/ subfolder. The Shen 2026 review is the **review-paper anchor** and Tevonian 2026 is the **research-paper anchor**. **Robin 业务对接**: 血管化类器官服务 + 多层血管网络平台 + 个性化精准医疗. Follow-ups: (a) add a wiki-side deep-read synthesis page at `/sources/literature-shen-2026-cmj-vascularized-organoids-review-deepread.md`; (b) cross-link with Tevonian 2026 to anchor a vascularized-organoid review-paper cluster; (c) verify whether the Chinese-language source yields any CelVivo-specific IRB or vascularization positioning material for Chinese-hospital customer conversations.
+
+### zhai-2026-skin-organoid-pemphigus-positioning: Zhai 2026 Sci Adv 3D skin pemphigus autoimmune dermatology positioning
+- Owner: me
+- Source: git-repo-1 2026-08-25 — vault commit `9d4767c7` (Zhai T et al. Sci Adv 2026 3D skin pemphigus, PMID 41512055, DOI 10.1126/sciadv.adz5003; vault path `obsidian-vault/04-Literature/Deep-Reads/Skin-Organoids/Zhai_2026_Sci_Adv_3D_Skin_Pemphigus.md`, **first file in new `Skin-Organoids/` subfolder**, **net-new application domain** — autoimmune dermatology + 3D skin)
+- Due: unscheduled
+- Status: open
+- Notes: **First 3D-skin organoid disease-modeling paper** in Robin's deep-read set; **net-new application domain** (autoimmune dermatology + 3D skin) that Robin's existing ~22 deep-read subfolders do not cover. Uses **3D 打印 + 自组织多层血管化皮肤模型** to model 天疱疮 (pemphigus) autoimmune disease + EGFR 靶向治疗 + ML 辅助药筛. **Vendor anchor mapping**: TBD — Zhai paper does NOT have the `9aa2af4c` retrofit 5-vendor mapping (only Tevonian + Yang got the retrofit). Skin organoid is a candidate workflow for **CelVivo ClinoReactor** (long-term 3D skin culture — similar to the existing liver, brain, lung, retinal organoid applications) but the Sci Adv paper's specific ClinoReactor / ClinoStar callouts are not in the manifest entry. **Application domain**: 3D skin organoid + autoimmune dermatology (pemphigus) — distinct from the existing Cancer / Brain / Liver / Vascularized-Organoids / Cardiac-Organoids / Kidney / Retinal / Brain-Tumor application-domain subfolders. **Robin 业务对接**: 皮肤自身免疫病药筛 + 3D 打印客户 + 精准医疗应用. Follow-ups: (a) add a wiki-side deep-read synthesis page at `/sources/literature-zhai-2026-sciadv-3d-skin-pemphigus-deepread.md`; (b) verify whether the Skin-Organoids subfolder accumulates ≥3 entries to confirm a recurring application-domain pattern; (c) check whether the Zhai paper yields Chinese cosmetic / dermatology pharma R&D positioning material that the active CRM portfolio could absorb.
+
 <!--
 Structure for new entries: